Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 13%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is well-positioned to capitalize on the growing demand for treatments for sleep disorders, particularly with its focus on developing orexin-based drugs. The company has shown promising results with alixorexton so far and has a strong pipeline of potential treatments in development. Additionally, Alkermes' partnerships with other companies and its use of proprietary technology give it a competitive advantage in the biotech industry. Furthermore, the company's strong financials, with a steady increase in revenue and a healthy balance sheet, provide a solid foundation for future growth and development.

Bears say

Alkermes is reliant on third-party partnerships for drug formulation which can lead to potential revenue volatility, and its current main revenue driver is in a highly competitive market with limited differentiation. In addition, their recent drug TAK-360 in phase 2 trials for NT2/IH has not yet been proven effective and has received little data, making it a risky investment.

Alkermes (ALKS) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 15 analysts, Alkermes (ALKS) has a Buy consensus rating as of Jul 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.